Neuroblastoma is a common pediatric malignancy that remains responsible for significant childhood cancer morbidity and mortality. Loss of heterozygosity (LOH) at chromosome band 1p36 occurs in up to one-third of primary neuroblastomas and a putative tumor suppressor gene has been mapped to subbands 1p36.2-3. However, the clinical significance of this rearrangement remains elusive, as all previous studies have been performed with a heterogenous sample of neuroblastomas treated in a non- uniform fashion over an extended time period. We hypothesize that 1p36 LOH independently predicts for relapse in patients whose tumors do not have MYCN amplification. First, we will determine the exact prevalence of 1p36 LOH in 300 neuroblastomas derived from a representative sample of patients from the most recent concurrent Children's Cancer Group phase III clinical trials. In addition, for all tumors with 1p LOH, we will map the extent of deletion and determine the parental origin of allelic loss to evaluate for evidence of genomic imprinting at this locus. Second, we will determine the clinical significance of 1p36 LOH. We plan to confirm our previous observation that 1p36 LOH is strongly associated with high-risk prognostic features. We will then determine the independent predictive power of 1p36 LOH to effect event-free and overall survival probability in stratified and multivariate analyses. Third, we will determine the prevalence and clinical significance of allelic loss at chromosome arms 11q and 14q, two other sites of frequent allelic loss that may harbor additional neuroblastoma suppressor genes. We will then correlate the 11q and 14q allelic status with known prognostic variables and survival. We have developed a fluorescence- based, semi-automated LOH detection system that will allow for simultaneous assessment of 15 separate polymorphic loci in a single experiment. Therefore, we anticipate efficient data collection and have made stringent plans to unambiguously assign LOH status for each locus. We expect that these studies will contribute significantly towards improving risk group assessment for neuroblastoma patients. This may lead to improvements in treatment stratification and allow for more specific therapy based upon tumor biology. These studies should also substantially contribute towards the positional cloning of three neuroblastoma suppressor genes and our basic understanding of the molecular genetics of this common pediatric tumor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA078966-02
Application #
2896680
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-08-01
Project End
2000-07-31
Budget Start
1999-08-03
Budget End
2000-07-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Attiyeh, Edward F; London, Wendy B; Mosse, Yael P et al. (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-53
Thompson, P M; Maris, J M; Hogarty, M D et al. (2001) Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 61:679-86
Weiss, M J; Guo, C; Shusterman, S et al. (2000) Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol 35:526-30
Hogarty, M D; Liu, X; Guo, C et al. (2000) Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 35:512-5
Guo, C; White, P S; Hogarty, M D et al. (2000) Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 35:544-6
Maris, J M; Weiss, M J; Guo, C et al. (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 18:1888-99
Guo, C; White, P S; Weiss, M J et al. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948-57
Maris, J M; Matthay, K K (1999) Molecular biology of neuroblastoma. J Clin Oncol 17:2264-79